Major Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Depressive DisordersPTSDAnxiety DisordersSubstance Use Disorders (SUD)Palliative & End-of-Life DistressSafety & Risk ManagementImplementation & Service DeliveryPsilocybin

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers

In an online survey of 1,221 people using psychedelics naturalistically, disclosure to clinicians was low (22% to primary care vs 58% to psychiatric providers), 81% wanted therapist support but only 15% received it, and 23% reported same-day use with potentially interacting psychiatric medications. These findings indicate a substantial disconnect between psychedelic use and clinical care with attendant safety risks, underscoring the need for improved clinician education and policy reforms oriented to harms and benefits.

Authors

  • Kevin Boehnke
  • Daniel Kruger
  • Moss Herberholz

Published

Frontiers in Psychiatry
individual Study

Abstract

Introduction

There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.

Methods

We conducted an online, anonymous, confidential, cross-sectional survey of adults reporting psychedelic use (N = 1221) through a psychedelics advocacy event and social media between 9/18/2022 and 11/5/2022. We assessed participant disclosure of psychedelic use with their psychiatric care provider (PsyCP) and/or primary care provider (PCP), desire for provider support, access to support, and rate of taking prescribed psychoactive medications alongside psychedelics.

Results

Among participants with such care providers, 22% disclosed psychedelic use to their PCP vs. 58% to their PsyCP. Participants were less confident in PCP vs. PsyCP ability to integrate psychedelics into treatment. Common reasons for nondisclosure included stigma, inadequate provider knowledge, and legal concerns. 23% reported taking psychedelics on the same day as potentially interacting psychiatric medications (e.g., anxiolytics, antidepressants). Despite 81% of participants desiring therapist support during psychedelic experiences, only 15% had received such support.

Discussion

Our results show that psychedelic use is generally disconnected from primary and psychiatric clinical care. This disconnection may result in safety issues, including inadequate screening for contraindicated conditions, lack of support during emergent adverse events, and drug interactions. Enhanced clinical education and orienting drug policy towards known harms and benefits of psychedelics is needed.

Available with Blossom Pro

Research Summary of 'Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers'

Introduction

Psychedelic research has expanded rapidly in recent years, driven by shifting policy landscapes and interest in alternative treatments for psychiatric conditions. Clinical trials have reported promising results for psychedelic-assisted psychotherapy across disorders such as major depression, treatment-resistant depression, cancer-related anxiety and depression, alcohol and tobacco dependence, and post-traumatic stress disorder; other compounds including MDMA, ayahuasca (DMT), ketamine, and LSD have also yielded therapeutic signals. At the same time, psychedelics remain criminalised under federal law in the United States for most compounds, new local decriminalisation initiatives are emerging, and naturalistic self-administration outside formal clinical settings appears to be increasing. Prior surveys suggest many people use psychedelics for mental health reasons but often do not disclose use to healthcare providers because of stigma, legal concerns, or doubts about provider knowledge, raising safety concerns such as contraindicated conditions and drug interactions. Boehnke and colleagues set out to characterise interactions between people who use psychedelics naturalistically and their healthcare providers. The study aimed to quantify disclosure of psychedelic use to primary care providers (PCPs) and psychiatric care providers (PsyCPs), assess participants’ desire for and access to professional support around psychedelic experiences, identify reasons for nondisclosure, and document concurrent use of prescribed psychoactive medications. The authors hypothesised that disclosure would be more common to PsyCPs than PCPs, while confidence in providers’ ability to integrate psychedelics into care would remain low despite a general desire for therapeutic support.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (23)

Papers cited by this study that are also in Blossom

Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States

Davis, A. K., Agin-Liebes, G. I., España, M. et al. · Journal of Psychoactive Drugs (2021)

Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey

Barnett, B. S., Beaussant, Y., King, K. et al. · Journal of Psychoactive Drugs (2021)

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Show all 23 references
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study

Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)

380 cited
Naturalistic Psychedelic Use: A World Apart from Clinical Care

Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

19 cited
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)

Serotonin toxicity of serotonergic psychedelics

Malcolm, B., Thomas, K. · Psychopharmacology (2021)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.